How does globus medical make money?

globus medical generates $2.9B in annual revenue (annual revenue · their business grew +16.7% last year).

What is GMED's XVARY composite score?

globus medical (GMED) has an XVARY composite score of 67/100, rated average. This combines growth, value, risk, and momentum factors.

GMED — globus medical stock analysis

Start here if you're new

what it is

Globus sells the hardware, software, and surgical tools doctors use to fix spines, joints, and nervous-system problems.

how it gets paid

Last year Globus Medical made $2.9B in revenue. Implantable devices was the main engine at $2.03B, or 70% of sales.

why it's growing
Revenue grew 16.7% last year. Demand trends for its spinal implants and musculoskeletal devices have shown notable strength of late.

what just happened

Revenue hit $2.1B, up 175% vs. prior year, while EPS jumped 230%.

At a glance

B++ balance sheet — above average — nothing keeping you up at night

40/100 earnings predictability — expect surprises

24.2x trailing p/e — priced about right

11.5% return on capital — nothing to write home about

xvary composite: 67/100 — average

What they do

Globus sells the hardware, software, and surgical tools doctors use to fix spines, joints, and nervous-system problems.

This business wins because surgeons do not casually swap out the gear they use inside your spine. Musculoskeletal Solutions were 94% of 2024 sales, which tells you the core implant franchise still pays the bills. The NuVasive merger also made Globus bigger overnight, and scale in medical devices means more reps in more operating rooms.

medical-devices mid-cap surgical-hardware merger-integration robotics

How they make money

$2.9B annual revenue · their business grew +16.7% last year

Implantable devices

$2.03B

Accessories

$0.32B

Instruments

$0.23B

Biologics

$0.15B

Enabling Technologies

$0.17B

The products that matter

designs and sells surgical implants

Spinal implants and musculoskeletal devices

$2.9B · +16.7% growth

It is the entire $2.9B business today, and it grew 16.7% last year. If you own GMED, this is the engine you are underwriting.

entire business

Key numbers

24.0%

eps growth

Projected earnings growth of 24.0% means profit is expected to rise much faster than the 13.5% projected sales growth. Plain English: the merger only matters if it makes each revenue dollar more profitable.

$120

18-month target

The 18-month target is $120 versus a $92.98 stock. Plain English: the current bull case is about a roughly 29% rerating if execution keeps improving.

16.3%

operating margin

Operating margin means how much money is left after running the business. Plain English: Globus keeps about 16 cents from each sales dollar before interest and taxes.

$4.0B

2029 revenue

Revenue is projected to reach $4.0 billion by 2029 from $2.9 billion now. Plain English: the market is paying for a bigger platform, not just a one-year bounce.

Financial health

B++

strength

balance sheet grade B++ — above average financial health
risk rank 3 — safer than 50% of stocks
price stability 45 / 100
net profit margin 17.0% — keeps 17 cents of every dollar in revenue
return on equity 12% — $0.12 profit for every $1 investors have put in

B++ — functional but not a standout on the balance sheet.

Total return vs. market

You invested $10,000 in GMED 3 years ago → it's now worth $12,370.

The index would have given you $14,770.

same period. same starting point. GMED trailed the market by $2,400.

source: institutional data · total return

What just happened

beat estimates

Revenue hit $2.1B, up 175% vs. prior year, while EPS jumped 230%.

The cleaner proof point was the company beating the last earnings estimate with $1.28 versus $1.13, a 13.27% surprise. Preliminary fourth-quarter sales of about $823 million also topped the $785 million Wall Street expected.

$2.1B

revenue

$2.90

eps

34.8%

gross margin

the number that mattered

$823 million in preliminary fourth-quarter sales mattered because it was roughly $38 million above the $785 million consensus, which says demand and integration both held up.

globus’ preliminary fourth-quarter results were encouraging.
leadership indicated that december-period sales likely came in around $823 million, representing vs. prior year growth of 25%.
the figure also implied a significant beat versus the $785 million that wall street had been targeting on average, with much of the upside coming from strength in the company’s core u.s. spine business.

gains in the enabling technologies unit, which management said was poised to deliver its best quarterly sales performance to date, provided additional support. globus is slated to release its official fourth-quarter and full-year 2025 results on february 24th.
the company appears well-positioned for continued improvement in 2026.
our model suggests that globus may flirt with double-digit earnings growth this year.

demand trends for its spinal implants and musculoskeletal devices have shown notable strength of late, and we anticipate this momentum will carry over in 2026, bolstered by strategic initiatives and further penetration of new and existing markets. benefits from recent acquisitions, including last year’s $250 million purchase of nevro, should also be increasingly supportive of core operations in 2026. all in all, we estimate that adjusted earnings will reach $4.35 a share this year, on sales of $3.2 billion. our calls are firmly within leadership’s current forecasts of $4.30-$4.40 and $3.18 billion-$3.22 billion.

source: company earnings report, 2026

What could go wrong

the #1 risk is securities-fraud litigation tied to recent disclosures.

∘

med

securities-fraud investigation

A law firm is investigating Globus Medical for potential securities fraud or unlawful business practices. Sometimes these go nowhere. Sometimes they become an expensive distraction. Either way, the headline keeps a ceiling on easy multiple expansion.

With the stock already at 24.2x trailing earnings, any escalation would pressure valuation before it hits the income statement.

∘

med

hospital pricing and reimbursement pressure

Hospitals still push on device pricing, and reimbursement policy can tighten procedure economics. That is not a side issue when your entire $2.9B business depends on hospitals continuing to buy and use these products.

This pressure runs straight at the 33.5% operating margin and 18.1% net margin that make the story attractive in the first place.

∘

med

integration and execution after Nevro

The $250M Nevro acquisition is now part of the growth narrative. If the integration drags, management gets two problems at once: slower growth and less confidence in future capital allocation.

You do not need a disaster here. Even a modest miss would matter because FY2026 expectations already sit at roughly $3.2B in revenue and $4.35 of EPS.

∘

med

earnings volatility

Earnings predictability is just 40/100. In human terms: this is not the kind of stock where every quarter arrives exactly on script.

That matters more when the shares are already near the top of a $52–$101 52-week range and the market is pricing in continued clean execution.

Pricing and reimbursement pressure touch essentially the full $2.9B revenue base, while any legal escalation would hit a stock already valued at 24.2x trailing earnings.

source: institutional data · regulatory filings · risk analysis

Pay attention to

earnings

official fourth-quarter release

The preannouncement was strong. Now you want the full report and guidance details that back up the $823M sales figure.

metric

fy2026 eps guide of $4.30–$4.40

If management lands near the top of that range, the valuation case looks better. If not, the multiple is less forgiving than it looks.

trend

revenue growth holding in the mid-teens

GMED grew 16.7% on a $2.9B base last year. That pace does not need to stay exact, but it does need to stay convincingly healthy.

risk

litigation and disclosure updates

The legal headline is not the operating story, but it is part of the stock story until it goes away or becomes something more serious.

Analyst rankings

short-term outlook

top 20%

Momentum score 2 — in human-speak, analysts expect above-average price performance over the next 12 months.

risk profile

average

Stability score 3 — this is a normal risk profile, not a bunker stock and not a casino chip.

chart momentum

average

Technical score 3 — the tape is constructive, but there is no dramatic signal hiding here.

earnings predictability

40 / 100

Low predictability means the quarterly path can stay noisy even when the long-term business looks fine.

source: institutional data

Institutional activity

institutions have been net buying for 3 consecutive quarters — 247 buyers vs. 236 sellers in 3q2025. total institutional holdings: 0.1B shares. net buying for 3 quarters.

source: institutional data · 1q2025-3q2025

source: institutional data

Price targets

3-5 year target range

$72 $168

$93 current price

$120 target midpoint · +29% from current · 3-5yr high: $130 (+40% · 9% ann'l return)

source: institutional data · analyst targets

The deep dive

GMED

xvary deep dive

gmed

the full analysis is in the works.

what you'll get

dcf valuation model

bull / base / bear scenarios

competitive moat breakdown

quarterly earnings tracker

operating model projections

risk matrix with kill criteria

original price target + conviction

updated with every earnings

free · no spam · you'll be first to read it

gmed

Get this snapshot in your inbox

Want the deeper analysis?